Novamed, Sanofi Point to Eurofarma Entry in CADE Review of Medley Deal

Novamed, Sanofi Point to Eurofarma Entry in CADE Review of Medley Deal
Photo: Adobe Stock 07.10.2026 1434

Novamed and Sanofi cite Eurofarma’s naratriptan entry and growing clomiphene use in opposing deeper scrutiny of their Medley deal.

Novamed and Sanofi have cited Eurofarma’s recent registration of a naratriptan drug and growing use of clomiphene citrate to treat male hypogonadism in response to the Brazilian competition authority’s decision to deepen its review of Novamed’s proposed acquisition of Medley. 

In their Oct. 2 response, the companies referred the Administrative Council for Economic Defense (CADE) to arguments submitted on Sept. 15 concerning competitive pressure in markets for fertility and migraine treatments. They also cited developments presented during subsequent meetings with the authority.

For clomiphene citrate, they argued that the drug faces competition not only from other fertility treatments, but also from testosterone-replacement therapies and other androgen treatments because of its growing off-label use to treat male hypogonadism. They also cited imports of the drug’s active pharmaceutical ingredient by other companies and supply through compounding pharmacies as alternative sources of competition.

For migraine treatments, Novamed and Sanofi argued that naratriptan competes with other triptans and therapeutic alternatives, and that the market remains open to new entry. In their Oct. 2 filing, they said that Eurofarma had recently obtained regulatory approval for a medicine containing naratriptan hydrochloride. The approval was published by Brazil’s health regulator on Sept. 10.

They also referred to information presented during meetings with CADE indicating that sales of clomiphene-citrate medicines tracked growth in the hypogonadism therapeutic-indication market in recent years, particularly by volume.

CADE declared the transaction complex on Sept. 17 and ordered further analysis of rivalry, entry conditions and competition in the retail markets for gonadotropins and other ovulation stimulants and selective serotonin agonists used to treat migraines. The authority also requested clarification concerning the non-retail market for prescription treatments for fungal infections of the genital and vulvar area.

CADE had invited the companies to submit evidence of efficiencies and propose possible remedies to competition risks identified in the review. The public version of the Oct. 2 response contains restricted passages and does not disclose whether Novamed and Sanofi offered additional information and/or proposed remedies.

Novamed notified the transaction to CADE under the full-form procedure on May 27. The authority subsequently examined its effects on government drug contracts, conducted an initial market test and sent additional questions to the parties and competitors. The authority's current statutory review deadline for the transaction is Jan. 22, 2027, but it can be extended for 90 days with a declaration of complexity.

Source: MLex

pharmaceutical markets  Brazil 

Share with friends

Related content